| Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million |
Company is advancing portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Lead candidate JADE-001 on track to enter the clinic in second half of 2025, with initial data expected in first half of 2026 The combined company will operate as “Jade Biosciences, Inc.” and will trade on Nasdaq under the ticker symbol “JBIO” SAN FRANCISCO and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the completion of its previously announced merger with Aerovate Therapeutics, Inc. (“Aerovate”). The combined company will operate as Jade Biosciences, Inc., with its shares expected to begin trading on the Nasdaq Capital Market on April 29, 2025, under the ticker symbol “JBIO. |
globenewswire.com |
2025-04-28 14:18:00 |
Czytaj oryginał (ang.) |
| Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals |
—Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass. , April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger. |
prnewswire.com |
2025-04-21 12:00:00 |
Czytaj oryginał (ang.) |
| Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences |
Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass. , April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement"). |
prnewswire.com |
2025-04-09 20:05:00 |
Czytaj oryginał (ang.) |
| Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences |
Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass. , April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate. |
prnewswire.com |
2025-04-07 12:30:00 |
Czytaj oryginał (ang.) |
| AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE |
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Aerovate Therapeutics, Inc. (NasdaqGM: AVTE) and Jade Biosciences. Pursuant to the terms of the agreement, shareholders of Aerovate will own approximately 1.6% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the m. |
businesswire.com |
2025-03-21 13:30:00 |
Czytaj oryginał (ang.) |
| AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aerovate Therapeutics, Inc. (NASDAQ: AVTE) and Jade Biosciences is fair to Aerovate shareholders. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company. Halper Sadeh encourages Aerovate shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212. |
businesswire.com |
2024-12-28 15:32:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. – AVTE |
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Aerovate Therapeutics, Inc. (Nasdaq: AVTE ), relating to a proposed merger with Jade Biosciences. Under the terms of the agreement, pre-merger Aerovate stockholders are expected to own approximately 1.6% of the combined company, while pre-merger Jade stockholders are expected to own approximately 98.4% of the combined entity. |
globenewswire.com |
2024-11-05 20:53:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. - AVTE |
NEW YORK , Nov. 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Aerovate Therapeutics, Inc. (Nasdaq: AVTE ), relating to a proposed merger with Jade Biosciences. |
prnewswire.com |
2024-11-03 17:47:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders |
NEW YORK , Nov. 1, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Aerovate Therapeutics, Inc. (NASDAQ: AVTE)'s merger with Jade Biosciences. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company. |
prnewswire.com |
2024-11-01 14:02:00 |
Czytaj oryginał (ang.) |
| AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aerovate Therapeutics, Inc. (NASDAQ: AVTE) and Jade Biosciences is fair to Aerovate shareholders. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company. Halper Sadeh encourages Aerovate shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212. |
businesswire.com |
2024-10-31 11:43:00 |
Czytaj oryginał (ang.) |
| Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders |
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Aerovate (Nasdaq: AVTE) for possible breaches of fiduciary duty and other violations of law in its transaction with Jade. Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. Under the agreement, Aerovate stockholders are expected to own approximately 1.6% of the combined company, while Jade stockholders — including those investors participating in the pre-clo. |
businesswire.com |
2024-10-31 11:31:00 |
Czytaj oryginał (ang.) |
| Aerovate Therapeutics to Explore Strategic Alternatives |
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. |
globenewswire.com |
2024-07-08 12:00:00 |
Czytaj oryginał (ang.) |
| The 3 Hottest Stock Downgrades From Last Week |
Wall Street's leading analysts have been adjusting their S&P 500 forecasts in recent days. Driven by potential Federal Reserve interest rate cuts, strong performance from large technology companies and solid corporate earnings growth, analysts expect the S&P 500 to consolidate its gains above 5500. |
investorplace.com |
2024-06-27 11:00:00 |
Czytaj oryginał (ang.) |
| Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC |
ATLANTA, June 21, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (NASDAQ: AVTE) complied with federal securities laws. On June 17, 2024, Aerovate announced topline results from the Phase 2b portion of the Phase 2b/Phase 3 Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial and stated that “the study did not meet its primary endpoint for improvement in pulmonary arterial hypertension (“PVR”) compared to placebo for any of the studied doses or show meaningful improvements in the secondary endpoint of change in six minute walk distance.” Following this news, the price of the Company's stock dropped. |
globenewswire.com |
2024-06-21 18:00:00 |
Czytaj oryginał (ang.) |
| Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm |
Investors can contact the law firm at no cost to learn more about recovering their losses |
globenewswire.com |
2024-06-20 17:22:00 |
Czytaj oryginał (ang.) |
| Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals |
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients. |
zacks.com |
2024-06-18 14:25:28 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Aerovate Therapeutics Investigated for Securities Fraud Violations by Block & Leviton |
BOSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Aerovate Therapeutics, Inc. (Nasdaq: AVTE) for potential securities law violations. Investors who have lost money in their Aerovate Therapeutics investment should contact the firm to learn more about how they might recover those losses. |
globenewswire.com |
2024-06-17 16:07:00 |
Czytaj oryginał (ang.) |
| Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension |
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses |
globenewswire.com |
2024-06-17 12:32:00 |
Czytaj oryginał (ang.) |
| Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market |
Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The global Pulmonary Arterial Hypertension market size is expected to reach $12.2 billion by 2032. Aerovate has been able to take what was achieved with oral Imatinib and convert it to a dry inhaled powder that can be used to treat pulmonary arterial hypertension. |
seekingalpha.com |
2024-06-11 17:19:13 |
Czytaj oryginał (ang.) |
| Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference |
Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHCT continues at more than 120 sites globally WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today presented a poster outlining baseline characteristics from all patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) at the American Thoracic Society (ATS) 2024 International Conference taking place in San Diego, CA. |
globenewswire.com |
2024-05-21 20:15:00 |
Czytaj oryginał (ang.) |
| Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights |
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended March 31, 2024, and recent business highlights. |
globenewswire.com |
2024-05-13 20:30:00 |
Czytaj oryginał (ang.) |
| Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference |
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster presentation at the 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, in San Diego, CA. The presentation will provide baseline characteristics from patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial evaluating the safety and efficacy of AV-101 in adults with pulmonary arterial hypertension. |
globenewswire.com |
2024-03-27 11:20:00 |
Czytaj oryginał (ang.) |
| Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights |
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the year ended December 31, 2023, and recent business highlights. |
globenewswire.com |
2024-03-25 18:10:00 |
Czytaj oryginał (ang.) |
| Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair |
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board. Mr. Dable succeeds Mark Iwicki, who will continue to serve on the Board. |
globenewswire.com |
2024-03-06 10:00:00 |
Czytaj oryginał (ang.) |
| Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension |
Topline Phase 2b data expected in June 2024 More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial WALTHAM, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) Phase 2b/Phase 3 study evaluating AV-101, a novel dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), has completed enrollment at 202 adult patients. |
globenewswire.com |
2023-11-20 18:45:00 |
Czytaj oryginał (ang.) |